Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 4/A

EAGLE PHARMACEUTICALS, INC. Form 4/A April 17, 2014 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading ProQuest Associates IV LLC Issuer Symbol EAGLE PHARMACEUTICALS, (Check all applicable) INC. [EGRX] (Last) (First) (Middle) 3. Date of Earliest Transaction Director X__ 10% Owner Other (specify Officer (give title (Month/Day/Year) below) below) 2430 VANDERBILT BEACH 02/18/2014 ROAD, 108-190 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person 02/20/2014 Form filed by More than One Reporting **NAPLES, FL 34109** Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired 5. Amount of 7. Nature of 1.Title of 2. Transaction Date 2A. Deemed 3. 6. Security (Month/Day/Year) Execution Date, if Transaction(A) or Disposed of Securities Ownership Indirect (Instr. 3) anv Code (D) Beneficially Form: Beneficial (Month/Day/Year) (Instr. 3, 4 and 5) Direct (D) Ownership (Instr. 8) Owned Following or Indirect (Instr. 4) Reported (I)(A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) (D) Price Code V Amount Common By ProQuest Stock, 02/18/2014 С 62,575 62,575⁽²⁾ I Management Α (1)\$0.001 par LLC Plans (3)value Common By ProQuest Stock, 02/18/2014 С 9.359 71,934 (2) I Management Α <u>(1)</u> \$0.001 par LLC Plans (3) value

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. 6. Date Exercisable and onNumber Expiration Date of (Month/Day/Year) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,		ate	7. Titl Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
r e e e e e e e e e	Director	10% Owner	Officer	Other			
ProQuest Associates IV LLC 2430 VANDERBILT BEACH ROAD, 108-190 NAPLES, FL 34109		Х					

Signatures

ProQuest Associates IV, LLC /s/ Pasquale DeAngelis, Managing Member ProQuest Investments IV, L.P. By ProQuest Associates IV LLC its GP /s/ Pasquale DeAngelis, Managing Member ProQuest Management LLC /s/Pasquale DeAngelis, Administrative Partner

**Signature of Reporting Person

Explanation of Responses:

If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock and (1) Series C Convertible Preferred stock automatically converted into one share of the Issuer's Common Stock on a 6.41-for-1 basis immediately prior to the consummation of the Issuer's initial public offering.

This amendment is being filed solely to correct the number of shares beneficially owned by the Reporting Person following the reported (2) transaction. Due to a ministerial error, the number of shares beneficially owned were improperly reflected in this line item on the original Form 4. No changes are required with respect to the information included on the original Form 4 as it relates to Table II.

(3) The shares are held in a ProQuest Management LLC Defined Benefit Pension Plan ("DBPP") FBO Jay Moorin and a ProQuest Management LLC Salary Savings Plan FBO Jay Moorin and for the benefit of certain other individuals. Jay Moorin and Alain Schreiber

04/17/2014

Date

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 4/A

are trustees of ProQuest Management LLC DBPP FBO Jay Moorin and the ProQuest Management LLC Salary Savings Plan FBO Jay Moorin and for the benefit of certain other individuals. Each of the Reporting Persons disclaims beneficial ownership of such securities except to the extent of each Reporting Person's pecuniary interest in such securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.